成纤维细胞生长因子受体3
生物
癌症研究
细胞凋亡
成纤维细胞生长因子受体
多发性骨髓瘤
成纤维细胞生长因子
细胞培养
成纤维细胞生长因子受体2
间质细胞
分子生物学
受体
免疫学
细胞生物学
遗传学
作者
Suzanne Trudel,Scott A. Ely,Yildiz Farooqi,Maurizio Affer,Davide F. Robbiani,Marta Chesi,Peter Leif Bergsagel
出处
期刊:Blood
[Elsevier BV]
日期:2004-01-12
卷期号:103 (9): 3521-3528
被引量:162
标识
DOI:10.1182/blood-2003-10-3650
摘要
We have previously shown that dysregulation of fibroblast growth factor receptor 3 (FGFR3) by the t(4;14) translocation is a primary event in multiple myeloma (MM) and that activating mutations of FGFR3 are acquired in some cases. We describe here inhibition of wild-type (WT) and constitutively activated mutant FGFR3 autophosphorylation by the small molecule inhibitor, PD173074. Inhibition of FGFR3 in human myeloma cell lines was associated with decreased viability and tumor cell growth arrest. Further, morphologic, phenotypic, and functional changes typical of plasma cell (PC) differentiation, including increase in light-chain secretion and expression of CD31, were observed and this was followed by apoptosis. Finally, using a mouse model of FGFR3 myeloma, we demonstrate a delay in tumor progression and prolonged survival of mice treated with PD173074. These results indicate that inhibition of FGFR3, even in advanced disease associated with multiple genetic changes, may allow the cell to complete its developmental program and render it sensitive to apoptotic signals. In addition, this represents the validation of a therapeutic target in MM that may benefit patients who have a very poor prognosis with currently available treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI